Harvard Bioscience appoints John Duke to board; incentive share pool increases 3.9M

HARVARD BIOSCIENCE INC

John Duke appointed to board effective June 2, 2025; will serve on audit and nominating committees.
Thomas Loewald resigned from board effective May 30, 2025; no disagreement cited.
Katherine Eade named Lead Independent Director.
Shareholders approved Amended and Restated 2021 Incentive Plan, increasing authorized shares by 3,923,000.
Non-binding advisory vote on executive compensation passed with 23.8M for vs 2.5M against.

item 5.02item 5.07item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John D. Duke

Director

HBIO · HARVARD BIOSCIENCE INC

Effective: 2025-06-02
Filed: Jun 02, 2025 23:59 UTC

On June 2, 2025, the Board appointed John D. Duke to serve as a member of the Board, June 2, 2025.

Departed

Thomas Loewald

Director

HBIO · HARVARD BIOSCIENCE INC

Effective: 2025-05-30
Filed: Jun 02, 2025 23:59 UTC

On May 30, 2025, Thomas Loewald informed the Company of his resignation from the board of directors (the “Board”) of Harvard Bioscience, Inc. (the “Company”), effective May 30, 2025.

Role change

Katherine Eade

Lead Independent Director

HBIO · HARVARD BIOSCIENCE INC

Effective: 2025-06-02
Filed: Jun 02, 2025 23:59 UTC

One June 2, 2025, the Board appointed Katherine Eade as the Board’s Lead Independent Director.

Source: SEC EDGAR

accession 0001171843-25-003574

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.